课题基金 / 基金详情

I-Corps: High Throughput Single Cell Assay Platforms

I-Corps: High Throughput Single Cell Assay Platforms
I-Corps:高通量单细胞检测平台
批准号:
1439409
负责人:
Euisik Yoon
金额:
$5.0万
依托单位国家:
美国
项目类别:
Standard Grant
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-05-01 至 2015-10-31

项目摘要

项目成果

Euisik Yoon的其他基金

相似基金

相关文献

中文摘要
翻译
该项目旨在商业化用于癌症药物筛选和癌症转移建模的高通量单细胞检测芯片。癌症是许多发达国家的主要死亡原因之一,癌症转移占癌症死亡的90%。传统的转移研究方法受到低通量或与体内微环境相关性差的限制。有一个未满足的需要,开发体外装置,可以模拟转移级联的关键步骤。除了建立体外肿瘤转移模型外,本研究还旨在为监测和分析癌细胞异质性提供解决方案。癌症耐药性是癌症治疗中最大的挑战之一。传统的药物开发方法只关注药物的平均疗效,不能针对整个肿瘤中的耐药肿瘤细胞,这可能导致肿瘤复发。在本应用中提出的原型平台提供了在单细胞分辨率下进行高通量分析的能力,这可以改变癌症研究和癌症治疗的范式。该平台还可以实现高通量筛选和体外转移模拟,从而显著降低药物开发成本。所提出的平台技术可以促进新治疗理念的发展,在高通量下具有较低的分析成本。所提出的设备具有很高的商业潜力,可以满足研究界和制药公司实现癌症药物开发和筛选的高通量低成本分析的需要。
英文摘要
This project aims to commercialize high-throughput single cell assay chips for cancer drug screening and modeling of cancer metastasis. Cancer is one of leading causes of death in many developed countries, and cancer metastasis accounts for 90% of the death caused by cancer. Conventional methods for studying metastasis are limited by low throughput or poor relevance to in-vivo microenvironment. There is an unmet need to develop in-vitro devices which can emulate critical steps of the metastatic cascade. In addition to the in-vitro cancer metastasis modeling, the proposed work aims to provide the solution to monitor and analyze cancer cell heterogeneity. Cancer drug resistance is one of the greatest challenges in cancer treatments. The conventional drug development methods used to focus on average drug efficacy and cannot target the drug resistant tumor cells in the whole tumor, which may lead to the relapse of tumor. The presented prototype platforms in this application provide the capability of high-throughput assays at single cell resolution, which can shift the paradigm of cancer research and cancer treatment. The proposed platforms also enable high-throughput screening and in-vitro metastasis emulation, resulting in significant reduction in drug development cost. The proposed platform technology can facilitate the development of novel therapeutic ideas with lower assay cost at high throughput. The proposed devices have a high commercial potential by meeting the need to realize high-throughput low-cost assays for cancer drug development and screening in research communities as well as pharmaceutical companies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NeuroNex Technology Hub: Multimodal Integrated Neural Technologies (MINT) - Connecting Physiology to Functional Mapping
PIRE: International Program for the Advancement of Neurotechnology (IPAN)
I-Corps: Implantable Brain-Computer Interface with Integrated Optics and Electrodes
High-Density Neural Recording Arrays with Monolithically-Integrated Nanopillar LEDs for Multi-Wavelength Optical Stimulation
海外基金